Phase 1 N=38 Randomized Quadruple-blind

Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment

Healthy

Bottom Line

View on ClinicalTrials.gov: NCT00644917 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2014

Primary outcome: Primary: Skin Reaction Score — 0.4; 0.5; 0.1; 0.4 units on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 1
Interventions: Xenaderm (Drug); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Healthpoint
Primary completion: Feb 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Skin Reaction Score	0.4; 0.5; 0.1; 0.4; 0.5; 0.3	—

Summary

The product is being tested to see if exposure to light causes toxic reactions on the skin.

Eligibility Criteria

Inclusion Criteria

Healthy subjects

Exclusion Criteria

Under 18 years of age

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00644917). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.